High-cylinder toric IOL better for high astigmatism

Article

Cataract patients who have astigmatism of greater than 2.5 D are likely to benefit more from the implantation of a high-cylinder toric intraocular lens (IOL) than from the implantation of a low-cylinder toric IOL combined with limbal relaxing incision (LRI), according to research conducted at the Ouchi Eye Clinic and Kyoto Prefectural University of Medicine, Kyoto, Japan

Cataract patients who have astigmatism of greater than 2.5 D are likely to benefit more from the implantation of a high-cylinder toric intraocular lens (IOL) than from the implantation of a low-cylinder toric IOL combined with limbal relaxing incision (LRI), according to research conducted at the Ouchi Eye Clinic and Kyoto Prefectural University of Medicine, Kyoto, Japan.

Fifty-seven eyes in 47 patients were studied. All of the eyes had preexisting corneal astigmatism of 2.5 D or greater. The eyes were divided into two treatment groups: One group (24 eyes) had a high-cylinder toric IOL (Alcon AcrySof IQ Toric T6, T7, T8 or T9) implanted. The other group (33 eyes) received the combination procedure of implantation of a low-cylinder toric IOL (Alcon Acrysof IQ Toric T5) and LRI. All of the procedures were performed by a single surgeon.

At 1 day postoperatively, patients in the group who received the high cylinder toric IOL had significantly better uncorrected visual acuity and significantly less manifest cylinder and refractive cylinder than patients who received the combination of a low-cylinder toric IOL and LRI. However, there was no significant difference in those parameters at 1 and 6 months postoperatively. The patients who received the combination low-cylinder IOL and LRI had significantly greater postoperative corneal and ocular higher-order aberrations.

"The findings of this study show that for the treatment of cataract patients with a high amount of astigmatism greater than 2.5 D, AcrySof IQ Toric T6, T7, T8 and T9 implantation can achieve better clinical outcomes, especially in the early postoperative period, than the combined procedure of AcrySof IQ Toric T5 implantation and LRI," the researcher reports.

The download the entire study, visit Clinical Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.